SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): ESG  SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement 08.08.2024 / 16:20 CET/CEST The issuer is solely responsible for the content of this announcement. SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement

August 8, 2024, Germany, Mainz

• SCHOTT Pharma is fully committed to take responsibility for emission reduction to support limitation of global warming to 1.5°C.
• The independent Science Based Targets initiative (SBTi) has validated the climate action roadmap and targets of the SCHOTT Group.
• SCHOTT Pharma will fulfil its share to these same validated science-based targets and report its progress transparently.
• The company focuses on energy efficiency, green electricity, and technological innovation to reduce greenhouse gas (GHG) emissions.

 SCHOTT Pharma, a pioneer in drug containment solutions and delivery systems, is reinforcing its commitment to reduce GHG emissions in alignment with climate science and the goal to limit global warming to 1.5°C.  The climate action roadmap of the SCHOTT Group was validated by the Science Based Targets initiative (SBTi). Recognizing the criticality of climate change, SCHOTT Pharma is dedicated to taking responsibility for its business operations' impact and contributing to global decarbonization efforts. “The time to act on climate change is now. We must all take responsibility – governments, society, and companies. At SCHOTT Pharma, it’s our priority to drive solutions for a more sustainable future. In particular, we are focusing on decarbonization through various initiatives ranging from green electricity use to low-emission manufacturing technology, ecodesign and circular economy,” said Dr. Almuth Steinkühler, CFO of SCHOTT Pharma.

In 2020, the SCHOTT Group launched its “Zero Carbon” program, driving decarbonization across all business units and subsidiaries. The initiative focuses on improving energy efficiency, utilizing green electricity, and initiating technological changes. Initially, the program has been aiming for climate-neutral operations concerning Scope 1 and Scope 2 GHG emissions by 2030. SCHOTT Pharma is a fully committed member of this initiative.